Our broad, long term objective is to understand the molecular details of Fc? receptor (Fc?R) function, with the goal of improving monoclonal antibody therapy for cancer. The antitumor effects of antibody therapy are largely mediated by Fc?R, which become clustered and activated upon binding to the Fc portion of antibodies. Monocytes and macrophages are essential for antibody therapy to be effective, and Fc?R activation in these cells can lead to pleiotropic responses. These include phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), production of inflammatory cytokines, or a combination of these. Amongst these activities, the mechanisms by which monocytes / macrophages carry out ADCC remain the least understood. We have recently found that Fc?R clustering can induce Granzyme B production by human monocytes and that ligands for Toll-like receptors (TLR) 4 and 8 can significantly enhance this response, as well as induce Granzyme B themselves. Granzyme B is a serine protease expressed predominantly by natural killer (NK) cells and CD8+ T cells, and is required for their cytotoxic functions. Given the central role of Granzyme B in NK cell- mediated ADCC, our finding that monocytes can also produce Granzyme B is remarkable as it provides an as- yet undiscovered anti-tumor function of monoclonal antibodies. Most notably we have also found that nurse- like cells (NLCs) generated from CLL patient blood also produce Granzyme B following Fc?R activation and TLR8 ligand treatment, and they can engage in Granzyme-dependent ADCC of CLL cells. This latter observation is of particular interest, as NLCs typically promote CLL-cell survival and proliferation. We therefore hypothesize that Granzyme B production by monocytes and NLCs represents a critical aspect of the effector response to antibody-coated target cells. We propose to explore the significance of these findings specifically related to CLL immunotherapy in the following 3 specific aims: 1) Elucidate the mechanisms of Granzyme B induction by Fc?R in monocytes/macrophages and NLCs, 2) Determine the mechanism of augmentation of Fc?R-induced Granzyme B production by immune modulators and 3) Analyze the expression and function of Granzyme B by monocytes and monocyte-lineage cells in patient samples and mouse models of CLL. Upon completion of this study we will have fully explored an entirely new mechanism of antibody-mediated destruction of tumors by monocytes/macrophages and NLCs. These mechanistic studies will significantly enhance our understanding of ADCC mediated by these cells, and will likely provide information that can lead to the further enhancement of antibody therapy.

Public Health Relevance

We have recently found that therapeutic antibodies can lead to the production of a tumor-attacking protease called Granzyme B by phagocyte-lineage cells in healthy donors and in chronic lymphocytic leukemia patients. This protease production can also be induced by immune-stimulating agents, which can also enhance the antibody-mediated protease production. These findings represent a novel means by which therapeutic antibodies lead to destruction of tumor cells, so we propose to examine the mechanisms and consequences of this protease production in detail with the goal of identifying new ways to enhance antibody therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA203584-01A1
Application #
9331881
Study Section
Special Emphasis Panel (ZRG1-OTC-K (03)M)
Program Officer
Howcroft, Thomas K
Project Start
2017-04-10
Project End
2022-03-31
Budget Start
2017-04-10
Budget End
2018-03-31
Support Year
1
Fiscal Year
2017
Total Cost
$347,783
Indirect Cost
$119,033
Name
Ohio State University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Fatehchand, Kavin; McMichael, Elizabeth L; Reader, Brenda F et al. (2016) Interferon-? Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells. J Biol Chem 291:25656-25666